Tenofovir is Associated With Higher Risk of Kidney Function Decline Than Entecavir in Patients With Chronic Hepatitis B
Clicks: 172
ID: 273317
2021
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
172 views
32 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #28 of 38 articles by views in clinical gastroenterology and hepatology : the official clinical practice journal of the american gastroenterological association
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Of the antiviral agents currently available to patients with chronic hepatitis B (CHB), entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are 2 of 3 first-line agents.1-3 Given the well-known renal and bone toxicity associated with TDF,4 major international hepatitis B vi …
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (40 words).
Try re-searching for a better abstract.
| Reference Key |
cy2021clinicaltenofovir
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Jung CY;Kim HW;Ahn SH;Kim SU;Kim BS;; |
| Journal | clinical gastroenterology and hepatology : the official clinical practice journal of the american gastroenterological association |
| Year | 2021 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.